請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89637
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬 | zh_TW |
dc.contributor.advisor | Mark Yen-Ping Kuo | en |
dc.contributor.author | 胡瑋凡 | zh_TW |
dc.contributor.author | Wei-Fan Hu | en |
dc.date.accessioned | 2023-09-13T16:11:05Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-13 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-07-11 | - |
dc.identifier.citation | 1. Berglundh T, Giannobile WV, Sanz M, Lang NP. Lindhe's Clinical Periodontology and Implant Dentistry: John Wiley & Sons, 2021.
2. Beaumont J, Chesterman J, Kellett M, Durey K. Gingival overgrowth: Part 1: aetiology and clinical diagnosis. Br Dent J 2017;222:85-91. 3. Bökenkamp A, Bohnhorst B, Beier C, Albers N, Offner G, Brodehl J. Nifedipine aggravates cyclosporine A-induced gingival hyperplasia. Pediatric nephrology 1994;8:181-185. 4. Bharti V, Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. Journal of Indian Society of Periodontology 2013;17:182. 5. Shimada T, Takemiya T, Sugiura H, Yamagata K. Role of inflammatory mediators in the pathogenesis of epilepsy. Mediators Inflamm 2014;2014:901902. 6. Trackman PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. Journal of dental research 2015;94:540-546. 7. Ibrahim M, Abouzaid M, Mehrez M, El Din HG, El Kamah G. Genetic disorders associated with gingival enlargement. Gingival Diseases-Their Aetiology, Prevention and Treatment: IntechOpen, 2011. 8. Luef G, Burtscher J, Kremser C, Birbamer G, Aichner F, Bauer G, et al. Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages. European neurology 1996;36:273-277. 9. Barclay CL, McLean M, Hagen N, Brownell AK, MacRae ME. Neurology 1992;42:2303. 10. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists 1991;2:103-137. 11. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia. A histochemical and ultrastructural study. Journal of periodontology 1985;56:211-215. 12. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. Journal of clinical periodontology 1996;23:165-175. 13. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210. 14. Corrêa JD, Queiroz-Junior CM, Costa JE, Teixeira AL, Silva TA. Phenytoin-induced gingival overgrowth: a review of the molecular, immune, and inflammatory features. International Scholarly Research Notices 2011;2011. 15. Kiwanuka E, Junker JP, Eriksson E. Transforming growth factor beta1 regulates the expression of CCN2 in human keratinocytes via Smad-ERK signalling. Int Wound J 2017. 16. Kantarci A, Cebeci I, Tuncer Ö, Çarin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A‐induced gingival hyperplasia. Journal of periodontology 1999;70:587-593. 17. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. Journal of periodontology 1999;70:967-972. 18. Thariny E. Comparison Of Gingival Overgrowth Status Between Drug Induced And Inflammatory Gingival Overgrowth. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO 2021:6040-6053. 19. Henderson J, Flynn J, Tucci M, Tsao A, Zebrowski E, Odium O, et al. Site‐specific variations in metabolism by human fibroblasts exposed to nifedipine in vitro. Journal of oral pathology & medicine 1997;26:6-10. 20. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral surgery, oral medicine, oral pathology 1984;57:620-622. 21. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. The American journal of cardiology 1980;46:1047-1058. 22. Seymour R, Heasman P. Drugs and the periodontium. Journal of clinical periodontology 1988;15:1-16. 23. McKevitt K, Irwin C. Phenotypic differences in growth, matrix synthesis and response to nifedipine between fibroblasts derived from clinically healthy and overgrown gingival tissue. Journal of oral pathology & medicine 1995;24:66-71. 24. Harel-Raviv M, Eckler M, Lalani K, Raviv E, Gornitsky M. Nifedipine-induced gingival hyperplasia. A comprehensive review and analysis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 1995;79:715-722. 25. Tipton DA, Fry H, Dabbous MK. Altered collagen metabolism in nifedipine‐induced gingival overgrowth. Journal of periodontal research 1994;29:401-409. 26. Barclay S, Thomason J, Idle J, Seymour R. The incidence and severity of nifedipine‐induced gingival overgrowth. Journal of clinical periodontology 1992;19:311-314. 27. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-705. 28. Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. The Journal of clinical investigation 2014;124:466-472. 29. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116:217-224. 30. Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008;10:333-342. 31. Schmierer B, Hill CS. TGFβ–SMAD signal transduction: molecular specificity and functional flexibility. Nature reviews Molecular cell biology 2007;8:970-982. 32. Rahimi RA, Leof EB. TGF‐β signaling: A tale of two responses. Journal of cellular biochemistry 2007;102:593-608. 33. Kim S, Jackson-Boeters L, Darling M, Rieder M, Hamilton D. Nifedipine induces periostin expression in gingival fibroblasts through TGF-beta. Journal of dental research 2013;92:1022-1028. 34. Flanders K, Sato M, Ooshima A, Russo A, Roberts A. Smad‐3 as a mediator of the fibrotic response. International journal of experimental pathology 2004;85:A13-A13. 35. Chen S-J, Yuan W, Mori Y, Levenson A, Varga J, Trojanowska M. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad 3. Journal of Investigative Dermatology 1999;112:49-57. 36. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, Stampfli M, et al. Smad3 null mice develop airspace enlargement and are resistant to TGF-β-mediated pulmonary fibrosis. The Journal of Immunology 2004;173:2099-2108. 37. Jeng JH, Lan WH, Wang JS, Chan CP, Ho YS, Lee PH, et al. Signaling mechanism of thrombin‐induced gingival fibroblast‐populated collagen gel contraction. British journal of pharmacology 2006;147:188-198. 38. Kuru L, Yilmaz S, Kuru B, Kose KN, Noyan U. Expression of growth factors in the gingival crevice fluid of patients with phenytoin-induced gingival enlargement. Archives of oral biology 2004;49:945-950. 39. Buduneli N, Kutukculer N, Aksu G, Atilla G. Evaluation of transforming growth factor-beta 1 level in crevicular fluid of cyclosporin A-treated patients. Journal of periodontology 2001;72:526-531. 40. Zeisberg M, Hanai J-i, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature medicine 2003;9:964-968. 41. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. The Journal of clinical investigation 2003;112:1486-1494. 42. Rygiel KA, Robertson H, Marshall HL, Pekalski M, Zhao L, Booth TA, et al. Epithelial–mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Laboratory investigation 2008;88:112-123. 43. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, Du Bois RM, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. The American journal of pathology 2005;166:1321-1332. 44. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nature medicine 2007;13:952-961. 45. Ribera J, Pauta M, Melgar-Lesmes P, Córdoba B, Bosch A, Calvo M, et al. A small population of liver endothelial cells undergoes endothelial-to-mesenchymal transition in response to chronic liver injury. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017;313:G492-G504. 46. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, et al. Endothelial–mesenchymal transition in bleomycin-induced pulmonary fibrosis. American journal of respiratory cell and molecular biology 2010;43:161-172. 47. Xavier S, Vasko R, Matsumoto K, Zullo JA, Chen R, Maizel J, et al. Curtailing endothelial TGF-β signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. Journal of the American Society of Nephrology 2015;26:817-829. 48. Garg K, Corona BT, Walters TJ. Therapeutic strategies for preventing skeletal muscle fibrosis after injury. Front Pharmacol 2015;6:87. 49. Yamada M, Kuwano K, Maeyama T, Yoshimi M, Hamada N, Fukumoto J, et al. Gene transfer of soluble transforming growth factor type II receptor by in vivo electroporation attenuates lung injury and fibrosis. J Clin Pathol 2007;60:916-920. 50. Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004;65:63-74. 51. Gagliardini E, Benigni A. Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 2006;17:89-96. 52. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000;32:247-255. 53. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005;29:121S-131S. 54. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 2010;120:3520-3529. 55. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827. 56. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84. 57. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007;8:813-824. 58. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 2012;69:2327-2343. 59. Jiang F, Liu GS, Dusting GJ, Chan EC. NADPH oxidase-dependent redox signaling in TGF-beta-mediated fibrotic responses. Redox Biol 2014;2:267-272. 60. Lampe V, Milobedzka J. Studien über curcumin. Berichte der deutschen chemischen Gesellschaft 1913;46:2235-2240. 61. Mansouri K, Rasoulpoor S, Daneshkhah A, Abolfathi S, Salari N, Mohammadi M, et al. Clinical effects of curcumin in enhancing cancer therapy: A systematic review. BMC cancer 2020;20:1-11. 62. Zheng D, Huang C, Huang H, Zhao Y, Khan MRU, Zhao H, et al. Antibacterial mechanism of curcumin: A review. Chemistry & Biodiversity 2020;17:e2000171. 63. Jakubczyk K, Drużga A, Katarzyna J, Skonieczna-Żydecka K. Antioxidant potential of curcumin—A meta-analysis of randomized clinical trials. Antioxidants 2020;9:1092. 64. Sun X, Liu Y, Li C, Wang X, Zhu R, Liu C, et al. Recent Advances of Curcumin in the Prevention and Treatment of Renal Fibrosis. Biomed Res Int 2017;2017:2418671. 65. Liu D, Gong L, Zhu H, Pu S, Wu Y, Zhang W, et al. Curcumin Inhibits Transforming Growth Factor beta Induced Differentiation of Mouse Lung Fibroblasts to Myofibroblasts. Front Pharmacol 2016;7:419. 66. Cousty S, Laurencin-Dalicieux S. Conclusion: Drug-Induced Oral Complications. Drug-Induced Oral Complications: Springer, 2021:121-122. 67. Stone RC, Pastar I, Ojeh N, Chen V, Liu S, Garzon KI, et al. Epithelial-mesenchymal transition in tissue repair and fibrosis. Cell and tissue research 2016;365:495-506. 68. Hayashi H, Sakai T. Biological Significance of Local TGF-beta Activation in Liver Diseases. Front Physiol 2012;3:12. 69. Kang JS, Liu C, Derynck R. New regulatory mechanisms of TGF-β receptor function. Trends in cell biology 2009;19:385-394. 70. Prime S, Pring M, Davies M, Paterson I. TGF-β signal transduction in oro-facial health and non-malignant disease (part I). Critical Reviews in Oral Biology & Medicine 2004;15:324-336. 71. Lin Y-C, Wu M-S, Lin Y-F, Chen C-R, Chen C-Y, Chen C-J, et al. Nifedipine modulates renal lipogenesis via the AMPK-SREBP transcriptional pathway. International journal of molecular sciences 2019;20:1570. 72. Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes. Molecular mechanisms in spermatogenesis 2008:154-171. 73. Deng YT, Wu KJ, Kuo MYP. Phenytoin induces connective tissue growth factor (CTGF/CCN2) production through NADPH oxidase 4‐mediated latent TGFβ1 activation in human gingiva fibroblasts: Suppression by curcumin. Journal of Periodontal Research 2022;57:1219-1226. 74. Shen K, Feng X, Su R, Xie H, Zhou L, Zheng S. Epigallocatechin 3-gallate ameliorates bile duct ligation induced liver injury in mice by modulation of mitochondrial oxidative stress and inflammation. PLoS One 2015;10:e0126278. 75. Umbarkar P, Singh S, Arkat S, Bodhankar S, Lohidasan S, Sitasawad SL. Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy. Free Radical Biology and Medicine 2015;87:263-273. 76. Yu J, Mao S, Zhang Y, Gong W, Jia Z, Huang S, et al. MnTBAP therapy attenuates renal fibrosis in mice with 5/6 nephrectomy. Oxidative medicine and cellular longevity 2016;2016. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89637 | - |
dc.description.abstract | Nifedipine 是一種常用來治療高血壓的藥物,但使用此藥物時,常會導致病人牙齦過度增 生(Gingival overgrowth,GO),進而影響病人的說話、吞嚥、咀嚼、口腔衛生和外貌等基 本功能,使生活品質受到嚴重影響。目前治療 GO 的主要方法是手術切除,但復發率高。許 多研究指出,在腫瘤轉移和器官纖維化等疾病中,上皮-間質轉換(Epithelial-mesenchymal transition,EMT)是重要的生物學現象,而轉型生長因子-β(Transforming growth factor-β, TGF-β)是誘導EMT的重要因子。除此之外,其在牙齦過度生長、纖維化等疾病中也扮演著重要角色。本研究發現,在處理 Nifedipine 24 小時後,人類牙齦上皮 Ca9-22 細胞株會出 現 EMT 現象,其中 E-cadherin 的表現量下降,Slug 的表現量上升,並且以 TGF-β 的中和抗體前處理後,可以抑制 Nifedipine 誘導的 EMT。前處理抗氧化劑 N-acetyl-cystenine(ROS 抑 制劑)、Mito-TEMPO(粒線體 ROS 抑制劑)、Diphenylene iodonium(NOX 抑制劑)、 Plumbagin(NOX4 抑制劑)、Apocynine(NOX2 抑制劑)可以抑制 Nifedipine 誘導的活化 態 TGF-β 的產生。而常見的天然食品成分薑黃素(Curcumin)可以抑制 Ca9-22 細胞中 Nifedipine 誘導的活化態 TGF-β 的釋放,進而抑制 TGF-β 下游的訊息傳遞。這些發現有助於 未來開發治療或預防 GO 的潛力藥物,例如薑黃素等。 | zh_TW |
dc.description.abstract | Nifedipine is a commonly used medication to treat hypertension, but its use often leads to gingival overgrowth (GO) in patients, which affects their basic functions such as speaking, swallowing, chewing, oral hygiene, and appearance, thus seriously impacting their quality of life. Currently, the main method to treat GO is surgical removal, but the recurrence rate is high. Many studies have pointed out that epithelial-mesenchymal transition (EMT) is an important biological phenomenon in diseases such as tumor metastasis and organ fibrosis, and transforming growth factor-β (TGF-β) is an important factor inducing EMT. In addition, it also plays an important role in diseases such as gingival overgrowth and fibrosis. This study found that after treating with Nifedipine for 24 hours, human gingival epithelial Ca9-22 cells exhibited EMT, with a decrease in the expression of Ecadherin and an increase in the expression of Slug. Further experiments showed that Nifedipine can induce the TGF-β signaling pathway, and pre-treatment with antioxidants such as N-acetylcystenine (ROS inhibitor), Mito-TEMPO(Mitochondria-targeted O 2 - inhibitor), Diphenylene iodonium (NOX inhibitor), Plumbagin (NOX4 inhibitor), and Apocynine (NOX2 inhibitor) can inhibit the production of activated TGF-β induced by nifedipine. The common natural food ingredient, curcumin, can inhibit the release of activated TGF-β induced by Nifedipine in Ca9-22 cells, thereby inhibiting downstream signaling of TGF-β. These findings may contribute to the development of potential drugs for treating or preventing GO, such as curcumin. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-13T16:11:05Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-13T16:11:05Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 III Abstract IV 目錄 V 圖目錄 VII 導論 1 第一章 牙齦過度增生 ( Gingival overgrowth ) 1 1-1 牙齦過度增生 1 1-2 藥物引發牙齦增生的流行病學 2 1-3 牙齦過度增生的可能致病機轉 2 1-4 牙齦過度增生的治療 3 第二章 尼菲迪平 (Nifedipine) 4 2-1 Nifedipine的簡介與作用機轉 4 2-2 Nifedipine與牙齦過度增生 4 第三章 乙型轉型生長因子-β (TGF-β) 5 3-1 TGF-β的簡介 5 3-2 TGF-β的訊息傳遞路徑 5 3-3 TGF-β與纖維化(牙齦過度增生) 6 第四章 活性氧化物 (Reactive oxygen species,ROS) 7 4-1 ROS的簡介 7 4-2 ROS與纖維化 7 第五章 薑黃素 ( Curcumin ) 8 研究目的 9 材料與方法 10 第一章 細胞株與細胞培養 10 第二章 藥物處理 10 第三章 西方墨點法 12 第四章Enzyme Linked Immunosorbent Assay (ELISA) 14 第五章 統計方法 15 結果 16 作用時長與作用濃度 16 Nifedipine誘導上皮-間質轉換 16 TGF-β、ALK4,5,7、Smad3抑制劑可抑制Nifedipine誘導上皮-間質轉換 16 Nifedipine經由ROS誘導牙齦細胞株釋放活化態TGF-β 17 薑黃素Curcumin可抑制Nifedipine釋放活化態TGF-β 17 討論 18 圖與表 20 參考文獻 26 | - |
dc.language.iso | zh_TW | - |
dc.title | 薑黃素抑制Nifedipine 經由活性氧化物誘導牙齦上皮細胞活化潛伏性TGF-β | zh_TW |
dc.title | Nifedipine activated latent TGF-β through reactive oxygen species in gingival epithelial cells: Suppression by curcumin | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 張瑞青;劉瑋文 | zh_TW |
dc.contributor.oralexamcommittee | Jenny Zwei-Chieng Chang;Wei-Wen Liu | en |
dc.subject.keyword | 尼菲迪平,牙齦過度增生,潛在的轉型生長因子,活性氧化物,上皮-間質細胞轉換, | zh_TW |
dc.subject.keyword | Nifedipine,Gingival overgrowth,Latent TGF-β,ROS,EMT, | en |
dc.relation.page | 33 | - |
dc.identifier.doi | 10.6342/NTU202301460 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-07-12 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 臨床牙醫學研究所 | - |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 8.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。